Eaton-Cambridge
ABBV icon

Eaton-Cambridge’s AbbVie ABBV Stock Holding History

Eaton-Cambridge’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$287K Buy
1,098
+48
+5% +$12.3K 0.08% 56
2026
Q2 		$264K Buy
1,050
+35
+3% +$7.53K 0.07% 57
2026
Q1 		$221K Buy
1,015
+110
+12% +$24.4K 0.07% 53
2025
Q4 		$207K Buy
+905
New +$206K 0.07% 44

Other funds holding ABBV

State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Amundi
Amundi Paris, France $496B AUM 35.36% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $348B AUM 26.9% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return

Eaton-Cambridge's ABBV Position: Q3 2026 in Review

Eaton-Cambridge increased its AbbVie (ABBV) stake by 4.6% in Q3 2026, buying an estimated $12.3K and bringing the position to 1,098 shares worth $287K. The position accounts for 0.08% of the portfolio, ranked #56.

Eaton-Cambridge first reported a position in ABBV in Q4 2025 and has held it in 4 quarters since. 3,222 funds tracked by Wall St. Rank hold ABBV as of Q3 2026.

  • Eaton-Cambridge held 1,098 shares of AbbVie worth $287K as of Q3 2026.
  • Eaton-Cambridge bought 48 AbbVie shares in Q3 2026, an estimated $12.3K.
  • AbbVie made up 0.08% of Eaton-Cambridge's portfolio in Q3 2026, its #56 holding.
  • Eaton-Cambridge first reported a position in AbbVie in Q4 2025 and has held it in 4 quarters since.
  • 3,222 funds tracked by Wall St. Rank held AbbVie as of Q3 2026.

Based on Eaton-Cambridge's 13F filing for Q3 2026, filed 10 Nov 2026.